COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results